Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,804
  • Shares Outstanding, K 67,133
  • Annual Sales, $ 180 K
  • Annual Income, $ -49,850 K
  • EBIT $ -57 M
  • EBITDA $ -56 M
  • 60-Month Beta 1.46
  • Price/Sales 382.55
  • Price/Cash Flow N/A
  • Price/Book 1.29

Options Overview Details

View History
  • Implied Volatility 514.74% (-6.25%)
  • Historical Volatility 81.33%
  • IV Percentile 87%
  • IV Rank 30.38%
  • IV High 1,430.17% on 04/17/25
  • IV Low 115.21% on 01/24/25
  • Expected Move (DTE 13) 0.2975 (27.29%)
  • Put/Call Vol Ratio 22.00
  • Today's Volume 46
  • Volume Avg (30-Day) 276
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 10,786
  • Open Int (30-Day) 10,866
  • Expected Range 0.7925 to 1.3875

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.20
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9201 +18.47%
on 12/03/25
1.1584 -5.90%
on 12/19/25
+0.0959 (+9.65%)
since 12/02/25
3-Month
0.9201 +18.47%
on 12/03/25
1.9400 -43.81%
on 11/11/25
-0.2900 (-21.01%)
since 10/02/25
52-Week
0.7113 +53.24%
on 05/28/25
2.7700 -60.65%
on 02/13/25
-1.4100 (-56.40%)
since 01/02/25

Most Recent Stories

More News
InflaRx (IFRX) Receives a Buy from Leerink Partners

In a report released yesterday, Joseph Schwartz from Leerink Partners reiterated a Buy rating on InflaRx, with a price target of $2.00. The company’s shares closed yesterday at $1.51.Elevate Your Investing...

IFRX : 1.0900 (+7.92%)
Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance

The revolutionary blockchain ecosystem from Infinitum, powered by Lusis-global leader in financial systems-sets a new standard in security, resilience, and interoperability, bridging traditional and decentralized...

IFRX : 1.0900 (+7.92%)
InflaRx N.V. Receives Positive CHMP Opinion for Marketing Authorization of GOHIBIC for COVID-19 Linked Acute Respiratory Distress Syndrome Treatment

The CHMP recommends marketing authorization for InflaRx's GOHIBIC to treat COVID-19 related ARDS in certain patients.Quiver AI SummaryInflaRx N.V. announced that the Committee for Medicinal Products for...

IFRX : 1.0900 (+7.92%)
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

IFRX : 1.0900 (+7.92%)
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes

June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...

IFRX : 1.0900 (+7.92%)
ESM23 : 4,453.35s (+0.61%)
HZON : 11.33 (+0.09%)
CFLT : 30.11 (-0.43%)
CAT : 598.41 (+4.46%)
VOLVB.S.DX : 296.950 (+0.02%)
NQM23 : 15,316.61s (+0.85%)
HTCR : 0.3147 (+3.11%)
MDB : 399.65 (-4.77%)
Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

IFRX : 1.0900 (+7.92%)
RJF : 163.60 (+2.22%)
Why Shares of InflaRx Are Soaring Wednesday

A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.

IFRX : 1.0900 (+7.92%)
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment

June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...

IFRX : 1.0900 (+7.92%)
ESM23 : 4,453.35s (+0.61%)
BE : 98.69 (+13.58%)
SGH : 20.85 (+0.43%)
JPM : 325.48 (+1.01%)
KRUS : 54.23 (+3.63%)
CI : 279.12 (+1.41%)
CAT : 598.41 (+4.46%)
JNJ : 207.35 (+0.19%)
NQM23 : 15,316.61s (+0.85%)
SW.FP : 43.100 (-1.37%)
InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...

IFRX : 1.0900 (+7.92%)
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...

IFRX : 1.0900 (+7.92%)

Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 1.2332
2nd Resistance Point 1.1765
1st Resistance Point 1.1333
Last Price 1.0900
1st Support Level 1.0334
2nd Support Level 0.9767
3rd Support Level 0.9335

See More

52-Week High 2.7700
Fibonacci 61.8% 1.9836
Fibonacci 50% 1.7406
Fibonacci 38.2% 1.4977
Last Price 1.0900
52-Week Low 0.7113

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar